Disc Medicine had its Relative Strength (RS) Rating upgraded from 63 to 74 Tuesday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
Can You Really Time The Stock Market?
IBD's unique rating tracks share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an 80 or better RS Rating as they begin their largest price moves. See if Disc Medicine can continue to show renewed price strength and clear that threshold.
Disc Medicine is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could kick off a new climb.
The company showed 0% earnings growth last quarter, while sales growth came in at 0%.
The company holds the No. 158 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
